Bora Pharmaceuticals CoTPE:6472 87 PE Ratio (TTM) is 18.50 as of Jul. 13, 2026, which is 16% below its 10-year median of 22.12. GuruFocus rates TPE:6472 with a GF Score™ of 87/100 and a GF Value™ of NT$719.77 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 639 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 56.03% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-13), Bora Pharmaceuticals Co's share price is
NT$426.00.
Bora Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$23.03. Therefore, Bora Pharmaceuticals Co's PE Ratio (TTM) for today is 18.50.
The historical rank and industry rank for Bora Pharmaceuticals Co's PE Ratio (TTM) or its related term are showing as below:
TPE:6472'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 6.81 Med: 22.12 Max: 191.13
Current: 18.5
During the past 13 years, the highest PE Ratio (TTM) of Bora Pharmaceuticals Co was 191.13. The lowest was 6.81. And the median was 22.12.
TPE:6472's PE Ratio (TTM) is ranked better than 56.03% of 639
companies
in the Drug Manufacturers industry
Industry Median: 20.77
vs TPE:6472: 18.50
During the past 12 months, Bora Pharmaceuticals Co's average EPS without NRIGrowth Rate was 58.70% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 41.80% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 72.60% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 71.80% per year.
During the past 13 years, Bora Pharmaceuticals Co's highest 3-Year average EPS without NRI Growth Rate was 141.30% per year. The lowest was -8.20% per year. And the median was 61.15% per year.
Bora Pharmaceuticals Co (TPE:6472) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Bora Pharmaceuticals Co PE Ratio (TTM) Related Terms
Bora Pharmaceuticals Co PE Ratio (TTM) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bora Pharmaceuticals Co PE Ratio (TTM) vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Bora Pharmaceuticals Co's PE Ratio (TTM) falls into.
Bora Pharmaceuticals Co PE Ratio (TTM) Calculation
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Bora Pharmaceuticals Co's Share Price of today is NT$426.00.
Bora Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$23.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Bora Pharmaceuticals Co (TPE:6472) has a PE Ratio (TTM) of 18.50 as of Jul. 13, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Bora Pharmaceuticals Co and its competitors. This is 16% below median its historical median of 22.12. Over the past decade, Bora Pharmaceuticals Co's PE Ratio (TTM) has ranged from 6.81 to 191.13. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #281 out of 639 companies in the Drug Manufacturers industry, placing it in the top 44%.
Is Bora Pharmaceuticals Co's PE Ratio (TTM) too high?
Bora Pharmaceuticals Co's current PE Ratio (TTM) of 18.50 is 16% below median its 10-year median of 22.12. Over the past 10 years, this metric has ranged from a low of 6.81 to a high of 191.13. The Drug Manufacturers industry median PE Ratio (TTM) is 20.77. Bora Pharmaceuticals Co's value of 18.50 is 10.9% below this industry median. Based on the distribution chart, Bora Pharmaceuticals Co ranks #281 out of 639 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bora Pharmaceuticals Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's PE Ratio (TTM) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #281 out of 639 companies for PE Ratio (TTM). This puts Bora Pharmaceuticals Co in the upper half of its industry. The industry median PE Ratio (TTM) is 20.77. Bora Pharmaceuticals Co's value of 18.50 is 10.9% below this benchmark. Historically, Bora Pharmaceuticals Co's own PE Ratio (TTM) has ranged from 6.81 to 191.13 over the past decade. While the company's 10-year median is 22.12 vs. the industry median of 20.77, Bora Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Drug Manufacturers company?
The median PE Ratio (TTM) among Drug Manufacturers companies is 20.77, based on 639 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bora Pharmaceuticals Co's current PE Ratio (TTM) of 18.50 is 10.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Bora Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median PE Ratio (TTM) is 20.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bora Pharmaceuticals Co's current PE Ratio (TTM) is 18.50, which is 16% below median its own 10-year median of 22.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$719.77, compared to a current price of NT$426.00 — trading 40.8% below its estimated fair value. The current PE Ratio (TTM) is 18.50, which is 16% below median its 10-year median of 22.12 and 10.9% below the Drug Manufacturers industry median of 20.77. Bora Pharmaceuticals Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current PE Ratio (TTM) is 18.50 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued.
The current stock price of NT$426.00 is trading 40.8% below its estimated GF Value™ of NT$719.77.
GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for TPE:6472:
PE Ratio (TTM): 18.50 (16% below median its 10-year median of 22.12)
GF Value™: NT$719.77 vs. price of NT$426.00 (40.8% below fair value)
Industry Position: 10.9% below the Drug Manufacturers median (#281 of 639)
No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
87GF Score
Get the complete analysis for TPE:6472
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6472 has been successfully added to your 
